1
|
Yun H, Wang K, Zhang J, Peng G, Zhao H. Construction of Peptide-Lipoic Acid Cationic Polymers with Redox Responsiveness and Low Toxicity for Gene Delivery. ACS OMEGA 2024; 9:3499-3506. [PMID: 38284089 PMCID: PMC10809251 DOI: 10.1021/acsomega.3c07194] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/19/2023] [Revised: 11/30/2023] [Accepted: 12/05/2023] [Indexed: 01/30/2024]
Abstract
As gene therapy continues to evolve, the development of safe and effective cationic polymer carriers is critical. In this work, three polymers have been prepared by ring-opening polymerization on the basis of peptide-lipoic acid monomers. By adjusting the sequence of the peptides, redox-responsive cationic polymers with different positive charge numbers were obtained, as well as investigating their performance as gene carriers. The results showed that the polymers complexed with negatively charged genes by electrostatic interaction and successfully transported the genes into the cells, additionally degrading and releasing the genes under glutathione (GSH) conditions. Furthermore, the polymers as gene carriers in different cell lines demonstrated lower cytotoxicity, with an excellent cell survival rate of 8 times higher than the "gold standard" polyethylenimine (PEI) at the same concentration. In vitro transfection experiments showed that the polymers successfully released and transfected genes into cells, demonstrating their immense potential in gene therapy.
Collapse
Affiliation(s)
- Hui Yun
- School
of Chemical Engineering, Sichuan University, Chengdu 610065, China
| | - Kang Wang
- School
of Chemical Engineering, Sichuan University, Chengdu 610065, China
| | - Jun Zhang
- Shandong
Pharmaceutical Glass Co., Ltd., Zibo 256100, China
| | - Guofeng Peng
- Shandong
Rike Chemical Co., Ltd, Changle 262400, China
| | - Hui Zhao
- School
of Chemical Engineering, Sichuan University, Chengdu 610065, China
| |
Collapse
|
2
|
Haji Abbasi Somehsaraie M, Fathi Vavsari V, Kamangar M, Balalaie S. Chemical Wastes in the Peptide Synthesis Process and Ways to Reduce Them. IRANIAN JOURNAL OF PHARMACEUTICAL RESEARCH : IJPR 2022; 21:e123879. [PMID: 36942077 PMCID: PMC10024322 DOI: 10.5812/ijpr-123879] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/06/2022] [Revised: 05/25/2022] [Accepted: 05/28/2022] [Indexed: 11/16/2022]
Abstract
In recent decades, a growing interest has been observed among pharmaceutical companies in producing and selling 80 FDA-approved therapeutic peptides. However, there are many drawbacks to peptide synthesis at the academic and industrial scales, involving the use of large amounts of highly hazardous coupling reagents and solvents. This review focuses on hideous and observant wastes produced before, during, and after peptide synthesis and proposes some solutions to reduce them.
Collapse
Affiliation(s)
| | - Vaezeh Fathi Vavsari
- Peptide Chemistry Research Institute, K. N. Toosi University of Technology, Tehran, Iran
| | - Mohammad Kamangar
- Peptide Chemistry Research Institute, K. N. Toosi University of Technology, Tehran, Iran
| | - Saeed Balalaie
- Peptide Chemistry Research Institute, K. N. Toosi University of Technology, Tehran, Iran
- Corresponding Author: Peptide Chemistry Research Institute, K. N. Toosi University of Technology, Tehran, Iran.
| |
Collapse
|
3
|
Sharma A, Kumar A, de la Torre BG, Albericio F. Liquid-Phase Peptide Synthesis (LPPS): A Third Wave for the Preparation of Peptides. Chem Rev 2022; 122:13516-13546. [PMID: 35816287 DOI: 10.1021/acs.chemrev.2c00132] [Citation(s) in RCA: 27] [Impact Index Per Article: 13.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
Since the last century, peptides have gained wide acceptance as drugs, with almost 100 already in the market and a large number in the pipeline. In this context, peptide synthesis has grown massively as a stringent field for pharmaceuticals around the globe. Three methodologies, namely, classical solution peptide synthesis (CSPS), solid-phase peptide synthesis (SPPS), and liquid-phase peptide synthesis (LPPS), have made significant contributions to the field. This review provides a comprehensive and integrated vision of LPPS as the third wave for peptide synthesis. LPPS combines the advantages of CSPS and SPPS, where peptide elongation is carried out in solution and the growing peptide chain is supported on a soluble tag, which confers characteristic properties. LPPS protocols allow the large-scale production of peptides and reduce the use of excess reagents and solvents, thus meeting the principles of green chemistry. In this review, tags associated with LPPS are broadly discussed under the following headings: polydisperse polyethylene glycol (PEG), membrane-enhanced peptide synthesis (MEPS), fluorous technology, ionic liquids (ILs), PolyCarbon, hydrophobic polymers, and group-assisted purification (GAP). It also highlights the signature accomplishments of LPPS tags and the limitations of the same.
Collapse
Affiliation(s)
- Anamika Sharma
- Peptide Science Laboratory, School of Chemistry and Physics, University of KwaZulu-Natal, Westville, Durban 4000, South Africa.,Department of Chemistry, Prayoga Institute of Education Research (PIER), Bangalore 560082, India
| | - Ashish Kumar
- Peptide Science Laboratory, School of Chemistry and Physics, University of KwaZulu-Natal, Westville, Durban 4000, South Africa.,KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa.,Anthem Biosciences Pvt. Ltd., No 49 Canara Bank Road, Bommasandra Industrial Area, Phase I Bommasandra, Bangalore 560099, India
| | - Beatriz G de la Torre
- KwaZulu-Natal Research Innovation and Sequencing Platform (KRISP), School of Laboratory Medicine and Medical Sciences, College of Health Sciences, University of KwaZulu-Natal, Durban 4041, South Africa
| | - Fernando Albericio
- Peptide Science Laboratory, School of Chemistry and Physics, University of KwaZulu-Natal, Westville, Durban 4000, South Africa.,Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, 08034 Barcelona, Spain.,CIBER-BBN, Networking Centre on Bioengineering, Biomaterials and Nanomedicine, and Department of Organic Chemistry, University of Barcelona, Martí i Franqués 1-11, 08028 Barcelona, Spain
| |
Collapse
|
4
|
Martin V, Egelund PHG, Johansson H, Thordal Le Quement S, Wojcik F, Sejer Pedersen D. Greening the synthesis of peptide therapeutics: an industrial perspective. RSC Adv 2020; 10:42457-42492. [PMID: 35516773 PMCID: PMC9057961 DOI: 10.1039/d0ra07204d] [Citation(s) in RCA: 41] [Impact Index Per Article: 10.3] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2020] [Accepted: 11/03/2020] [Indexed: 12/13/2022] Open
Abstract
Solid-phase peptide synthesis (SPPS) is generally the method of choice for the chemical synthesis of peptides, allowing routine synthesis of virtually any type of peptide sequence, including complex or cyclic peptide products. Importantly, SPPS can be automated and is scalable, which has led to its widespread adoption in the pharmaceutical industry, and a variety of marketed peptide-based drugs are now manufactured using this approach. However, SPPS-based synthetic strategies suffer from a negative environmental footprint mainly due to extensive solvent use. Moreover, most of the solvents used in peptide chemistry are classified as problematic by environmental agencies around the world and will soon need to be replaced, which in recent years has spurred a movement in academia and industry to make peptide synthesis greener. These efforts have been centred around solvent substitution, recycling and reduction, as well as exploring alternative synthetic methods. In this review, we focus on methods pertaining to solvent substitution and reduction with large-scale industrial production in mind, and further outline emerging technologies for peptide synthesis. Specifically, the technical requirements for large-scale manufacturing of peptide therapeutics are addressed.
Collapse
Affiliation(s)
- Vincent Martin
- Novo Nordisk A/S, CMC API Development Smørmosevej 17-19 DK-2880 Bagsværd Denmark +45 4444 8888
| | - Peter H G Egelund
- Novo Nordisk A/S, CMC API Development Smørmosevej 17-19 DK-2880 Bagsværd Denmark +45 4444 8888
| | - Henrik Johansson
- Novo Nordisk A/S, CMC API Development Smørmosevej 17-19 DK-2880 Bagsværd Denmark +45 4444 8888
| | | | - Felix Wojcik
- Novo Nordisk A/S, CMC API Development Smørmosevej 17-19 DK-2880 Bagsværd Denmark +45 4444 8888
| | - Daniel Sejer Pedersen
- Novo Nordisk A/S, CMC API Development Smørmosevej 17-19 DK-2880 Bagsværd Denmark +45 4444 8888
| |
Collapse
|
5
|
Isidro-Llobet A, Kenworthy MN, Mukherjee S, Kopach ME, Wegner K, Gallou F, Smith AG, Roschangar F. Sustainability Challenges in Peptide Synthesis and Purification: From R&D to Production. J Org Chem 2019; 84:4615-4628. [PMID: 30900880 DOI: 10.1021/acs.joc.8b03001] [Citation(s) in RCA: 196] [Impact Index Per Article: 39.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
In recent years, there has been a growing interest in therapeutic peptides within the pharmaceutical industry with more than 50 peptide drugs on the market, approximately 170 in clinical trials, and >200 in preclinical development. However, the current state of the art in peptide synthesis involves primarily legacy technologies with use of large amounts of highly hazardous reagents and solvents and little focus on green chemistry and engineering. In 2016, the ACS Green Chemistry Institute Pharmaceutical Roundtable identified development of greener processes for peptide API as a critical unmet need, and as a result, a new Roundtable team formed to address this important area. The initial focus of this new team is to highlight best practices in peptide synthesis and encourage much needed innovations. In this Perspective, we aim to summarize the current challenges of peptide synthesis and purification in terms of sustainability, highlight possible solutions, and encourage synergies between academia, the pharmaceutical industry, and contract research organizations/contract manufacturing organizations.
Collapse
Affiliation(s)
- Albert Isidro-Llobet
- Medicines Research Centre , GlaxoSmithKline , Gunnels Wood Road , Stevenage SG1 2NY , U.K
| | - Martin N Kenworthy
- Pharmaceutical Technology and Development , AstraZeneca , Silk Road Business Park, Charter Way , Macclesfield SK10 2NA , U.K
| | - Subha Mukherjee
- Chemical and Synthetic Development , Bristol-Myers Squibb Company , One Squibb Drive , New Brunswick , New Jersey 08903 , United States
| | - Michael E Kopach
- Small Molecule Design and Development , Eli Lilly and Company , 1400 West Raymond Street , Indianapolis , Indiana , United States
| | - Katarzyna Wegner
- Active Pharmaceutical Ingredient Development , IPSEN Manufacturing Ireland, Ltd. , Blanchardstown Industrial Park , Dublin 15 , Ireland
| | - Fabrice Gallou
- Chemical & Analytical Development , Novartis , 4056 Basel , Switzerland
| | - Austin G Smith
- Drug Substance Process Development , Amgen, Inc. , 1 Amgen Center Drive , Thousand Oaks , California 91320 , United States
| | - Frank Roschangar
- Chemical Development , Boehringer Ingelheim Pharmaceuticals , Ridgefield , Connecticut 06877 , United States
| |
Collapse
|
6
|
|